Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 383

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Open access
Shaw, Alice T., Solomon, Benjamin J., Besse, Benjamin, Bauer, Todd M., Lin, Chia-Chi, Soo, Ross A., Riely, Gregory J., Ou, Sai-Hong Ignatius, Clancy, Jill S., Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D. Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M., Felip, Enriqueta, Martini, Jean-François·2019·Journal of Clinical Oncology

Abstract

PURPOSE: Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non–small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that ALK resistance mutations may represent a biomarker of response in previously treated patients. PATIENTS AND METHODS: Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non–small-cell lung cancer from the registrational phase II study of lorlatinib. We analyzed plasma DNA for ALK mutations using Guardant360. Tumor tissue DNA was analyzed using an ALK mutation–focused next-generation sequencing assay. Objective response rate, duration of response, and progression-free survival were evaluated according to ALK mutation status. RESULTS: Approximately one quarter of patients had ALK mutations detected by plasma or tissue genotyping. In patients with crizotinib-resistant disease, the efficacy of lorlatinib was comparable among patients with and without ALK mutations using plasma or tissue genotyping. In contrast, in patients who had failed 1 or more second-generation ALK TKIs, objective response rate was higher among patients with ALK mutations (62% v 32% [plasma]; 69% v 27% [tissue]). Progression-free survival was similar in patients with and without ALK mutations on the basis of plasma genotyping (median, 7.3 months v 5.5 months; hazard ratio, 0.81) but significantly longer in patients with ALK mutations identified by tissue genotyping (median, 11.0 months v 5.4 months; hazard ratio, 0.47). CONCLUSION: In patients who have failed 1 or more second-generation ALK TKIs, lorlatinib shows greater efficacy in patients with ALK mutations compared with patients without ALK mutations. Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.02236

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 383

Metadata

Authors
Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C.-C., Soo, R. A., Riely, G. J., Ou, S.-H. I., Clancy, J. S., Li, S., Abbattista, A., Thurm, H., Satouchi, M., Camidge, D. R., Kao, S., Chiari, R., Gadgeel, S. M., Felip, E., & Martini, J.-F.
Venue
Journal of Clinical Oncology
Published
2019-06-01
Volume
37
Issue
16
Pages
1370-1379
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2923683745
Cited by
383
References
28
FWCI
36.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.18.02236
The paper
Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C.-C., Soo, R. A., Riely, G. J., Ou, S.-H. I., Clancy, J. S., Li, S., Abbattista, A., Thurm, H., Satouchi, M., Camidge, D. R., Kao, S., Chiari, R., Gadgeel, S. M., Felip, E., & Martini, J.-F. (2019). ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.02236

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.